Aducanumab

Nov 28, 2017

Decision Resources Group Projects Explosive Growth of the Alzheimer's Disease Market if Emerging Agents Can Beat the Odds and Deliver Phase III Success

Nov 09, 2017

Neurimmune Announces Collaboration With Ono Pharmaceutical in Neurodegenerative Diseases Field

Oct 17, 2017

ProMIS Neurosciences Lead Product Candidate, PMN310, Shows Desired Target Binding Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies for Alzheimer's Disease